Showing 7871-7880 of 8465 results for "".
- Advancing Age May Affect Psoriasis Patients' Access to Biologicshttps://practicaldermatology.com/news/advancing-age-may-affect-psoriasis-patients-access-to-biologics/2458746/Elderly psoriasis patients may be less likely to receive biologics, according to a new study out of Umeå University in Sweden. Specifically, an age increase of 30 years resulted in an average 65 percent reduction in likelihood of obtaining treatment with biologics in this population
- ASDS Announces President's Award Recipientshttps://practicaldermatology.com/news/asds-announces-presidents-award-recipients/2458752/The American Society for Dermatologic Surgery honored four of its members with a President’s Award for contributing to the Society or the medical specialty in an extraordinary or unique way. George J. Hruza, MD, MBA, presented the awards in his final d
- Almirall Exercises Call Option to Acquire ThermiGenhttps://practicaldermatology.com/news/almirall-exercises-call-option-to-acquire-thermigen/2458755/Barcelona pharma company Almirall, S.A., is stepping up their plans to take on ThermiGen LLC. The company is now exercising their call option to acquire 100 percent of the share capital of ThermiGen.
- AADA Provides Input on Skin Cancer Screening Recommendationhttps://practicaldermatology.com/news/aada-provides-input-on-skin-cancer-screening-recommendation/2458761/Recognizing the importance of early detection, the American Academy of Dermatology Association (AADA) has responded to the U.S. Preventive Services Task Force Draft Recommendation Statem
- Anacor Submits NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitishttps://practicaldermatology.com/news/anacor-submits-nda-for-crisaborole-topical-ointment-2-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/2458765/Anacor Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the US FDA seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic d
- Allergan Expands Neurotoxin Pipeline with Anterios Acquisitionhttps://practicaldermatology.com/news/allergan-expands-neurotoxin-pipelinewith-anterios-acquisition/2458763/Allergan plc has acquired Anterios, Inc., a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential devel
- Vyome Biosciences Announces FDA Acceptance of Investigational New Drug Application for VB-1953 to Treat Acnehttps://practicaldermatology.com/news/vyome-biosciences-announces-fda-acceptance-of-investigational-new-drug-application-for-vb-1953-to-treat-acne/2458766/The FDA accepted Vyome Biosciences’ Investigational New Drug (IND) Application for the initiation of clinical studies for VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon. “Today m
- Paratek To Complete Omadacycline Phase 3 Skin Trial Earlier Than Expectedhttps://practicaldermatology.com/news/paratek-completes-enrollment-for-omadacycline-phase-3-skin-trial-earlier-than-expected/2458767/Paratek Pharmaceuticals, Inc. may report top-line data from its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSS
- Immune and BioNanoSim Enter Agreement to Develop Novel Topical Nano-Capsule Formulation of Cyclosporinehttps://practicaldermatology.com/news/immune-and-bionanosim-enter-agreement-to-develop-novel-topical-nano-capsule-forumlation-of-cyclosporine/2458768/Immune Pharmaceuticals Inc. entered into an exclusive worldwide licensing and development agreement with BioNanoSim Ltd. for a novel topical nano-capsule formulation of cyclosporine, also known as cyclosporine-A or CsA. Monica Luchi, M.D., Chief Medical Officer of Immune, commented: "
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015